• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Aerie Pharmaceuticals

edit

Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

Recent Milestones

edit

• 
  Aerie Pharmaceuticals received $30M in Series B funding. (3/7/11)
  Posted 3/3/11 at 8:43pm via aeriepharma.com
• 
  Aerie Pharmaceuticals added Casey C. Kopczynski as Chief Research Officer and Co-Founder.
  Posted 3/4/11 at 3:42am
• 
  Aerie Pharmaceuticals added Thomas J. van Haarlem as President and CEO.
  Posted 3/3/11 at 8:43pm
• 
  Aerie Pharmaceuticals added Mitchell deLong as Vice-President, Chemistry R&D.
  Posted 3/4/11 at 3:42am

Videos

Screenshots

edit

Above: Aerie Pharmaceuticals
Uploaded: 3/4/11

Sources

1. Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio (aeriepharma.com) [edit]